BioMed Nexus Daily Updates
Your essential biotech, medtech, and pharma recap — no noise, just what matters.
Friday, October 2, 2026
📌TL;DR
Regeneron's trevogrumab preserved up to 71.8% of the muscle volume otherwise lost on semaglutide over 52 weeks in the Phase 2 COURAGE trial, per Regeneron's release; the results are in press at The Lancet.
Survodutide cut weight up to 13.1% versus 3.1% for placebo over 76 weeks in the Phase 3 SYNCHRONIZE-2 trial in obesity or overweight with type 2 diabetes, per Zealand Pharma and Boehringer Ingelheim; the results published in The New England Journal of Medicine.
Sanofi will pay Regeneron $1 billion upfront, with up to $7 billion in milestones, for a 50:50 alliance on four long acting immunology antibodies targeting IL-13, IL-4 and IL-4Rα, per Sanofi's release.
Foghorn and Eli Lilly dropped FHD-909 and their SMARCA2 collaboration on insufficient efficacy; Foghorn is cutting about 40% of staff and FHTX fell 18.2%.
Cullinan and Taiho initiated a rolling NDA for first line zipalertinib plus chemotherapy under the FDA's Real Time Oncology Review program, on REZILIENT3 data showing median progression free survival of 14.5 versus 8.5 months.
Axogen completed its BioCircuit acquisition after the close, adding NerveTape, the first FDA cleared device for sutureless peripheral nerve repair; the GENEROUS final state count remains unpublished two days past its deadline.
⚡ Executive Takeaway
On Monday we set the week's through line: watch the delivery layer, because the molecules are converging. The week graded it generously, then extended it. Kodiak showed an interval can win a Phase 3 outright. Lilly showed titration schedules and an oral route are now the competitive weapons. And Thursday supplied the control arm of the whole thesis: survodutide, a perfectly competent dual agonist that met every endpoint, differentiated on nothing, and got marked down anyway. When a molecule converges on the class average and brings no delivery story, no composition story, and no tolerability story, the market now treats a successful Phase 3 as bad news. That is new.
The extension is COURAGE. Regeneron's 52 week data moves the fight to a third layer beyond molecule and delivery: what the lost weight is made of. Muscle preservation held near 70% on MRI through a full year, and a dedicated trial in older adults will test whether that becomes a claim payers price. One week, three layers, and the cheapest seat at the table is still the molecule. Next week's through line sets Monday.
💪 Obesity and Muscle
The next fight in obesity is what the lost weight is made of, and Regeneron just posted the first 52 week answer. REGN
Regeneron's Phase 2 COURAGE release shows trevogrumab preserved 42.5% of the lean mass and 71.8% of the MRI measured muscle volume otherwise lost on semaglutide at 52 weeks in the 25 mg and 75 mg portion, with adverse events at 77% versus 82% on placebo and the paper in press at The Lancet. The release also resolves the dose label conflict that led us to cut the wire figures on Tuesday: the trial ran two independent portions, 200 and 400 mg in the 2025 readout and 25 and 75 mg in this one, so both label sets were real. That cut was the protocol working as designed, and the primary has now paid it off. Next is a Phase 2 in older adults with obesity and low muscle mass and strength, the population where this becomes a reimbursable claim or does not. REGN closed down 3.1% on the day it posted these data and banked $1 billion from Sanofi; we assign no cause.
⚖️ Obesity Competition
Survodutide met every endpoint in Phase 3 and still lost ground, because 13.1% no longer clears the class bar. NVO | LLY
SYNCHRONIZE-2 randomized 755 adults with obesity or overweight and type 2 diabetes to once weekly survodutide or placebo for 76 weeks: weight fell up to 13.1% versus 3.1%, HbA1c fell up to 1.21 points, and discontinuation for gastrointestinal events ran 18% versus 1.2%, per the sponsors' release. The NEJM publication, as reported by Fierce Biotech, puts the treatment policy estimand at 9.8% versus 3.9%, with 39% vomiting and 26% stopping for adverse events. Against the same week's 23.3% from EloraTZP and 20.8% from retatrutide, on each sponsor's own figures, the dual agonist now needs its cardiovascular outcomes trial, due later in 2026, to find a lane. Zealand fell 11% in Copenhagen by midday, per Fierce Biotech; BMO called the profile less competitive, a view we print as theirs.
🤝 Immunology
Sanofi paid $1 billion upfront to run the Dupixent playbook again before anyone else can. SNY | REGN
The expanded alliance covers four long acting antibodies: an IL-13 already in Phase 1, an IL-4xIL-13 bispecific, an IL-4, and an IL-4Rα antibody, with up to $7 billion in milestones, a 50:50 profit split, shared costs, and Dupixent economics untouched, per Sanofi's release. Three of the four work the exact pathway Dupixent owns, and one aims at Dupixent's own receptor. This is franchise succession, not diversification: the partners are paying to compete with themselves on dosing interval before a rival or a biosimilar does it for them. Sanofi also took an option on its lunsekimig TSLP/IL-13 bispecific after its Phase 3 COPD readout.
🧬 R&D
One of oncology's cleanest genetic hypotheses just failed its best resourced test. FHTX | LLY
Foghorn and Lilly will not advance FHD-909, their SMARCA2 inhibitor for SMARCA4 mutant cancers, and are dropping the companion degrader program: safety was favorable at exposures above preclinical targets, but the synthetic lethality did not translate into sufficient efficacy, per Foghorn's release, which is unusually plain about the science. Foghorn is cutting about 40% of staff, stretching cash into the second half of 2029, and refocusing on its EP300 and CBP degraders and an oral immunology program. FHTX closed down 18.2%. The readacross is the story: after PARP, paralog logic was the field's cleanest argument, and every program built on it just inherited a heavier burden of proof.
🫁 Oncology Regulatory
Zipalertinib opened a second FDA track five months before its first one decides. CGEM
Cullinan and Taiho began a rolling NDA for zipalertinib plus chemotherapy in first line EGFR exon 20 insertion lung cancer under Real Time Oncology Review, on REZILIENT3 interim data showing median progression free survival of 14.5 versus 8.5 months, per the companies' release, which crossed at 7:30 pm Eastern. Submission completion is expected by year end; the monotherapy NDA already under review has a February 27, 2027 action date. The release landed after the close, so Friday is the first reaction session. Cullinan's milestones are concrete: $30 million on a second line approval, $100 million on first line.
🏥 Medtech and Policy
Device hardware had its best day of the week after the close. AXGN
Axogen completed its BioCircuit acquisition at 5:19 pm Eastern, adding NerveTape, the first FDA cleared device for sutureless peripheral nerve repair, per its release; Friday is the first reaction session. In Washington, the US-China Board of Trade recommended reduced tariff treatment on roughly $30 billion of imports per side, with medical devices explicitly on the US export list, per MedTech Dive quoting USTR Jamieson Greer; no amounts or dates yet, and we will treat the recommendation as real when a legal instrument exists. For operators the two items rhyme: hardware differentiation and trade plumbing are both delivery layer questions, just for devices instead of peptides.
📋 Quick Hits
The GENEROUS final signed state count remains unpublished two days past the September 30 deadline; we checked the CMS newsroom index at roughly 8:15 pm Pacific Thursday. The last official figure is September 18: 40 states plus Puerto Rico signed, all 50 plus DC and Puerto Rico applied.
No AstraZeneca/Summit closing 8-K had appeared as of Thursday night, our search scope; the release's window runs to about October 5, so the absence becomes printable next week.
Novo's post hoc STEP UP pooled analysis showed injectable semaglutide cut liver fat from 8.8% to 3.1% at week 72 in a 55 participant imaging subgroup, per its release, which labels the analysis exploratory.
Oura postponed its up to $2.2 billion IPO citing market uncertainty, per MedTech Dive's September 29 report, and BioSpace tallied Q3 biopharma M&A at just under $30 billion across 22 deals.
Still absent Thursday night, scopes per our searches: the Atebrioz launch price (the October watch is open), pricing documents for Fayuvi, Isembyld and Lyrfigtu, and any GSK flu Phase 3 start release.
📖 In Today's Full Analysis
Be sure to read the full article for all the details, including:
The full COURAGE tables, both portions, with the preservation arithmetic at 26 and 52 weeks
The obesity readout board: EloraTZP, retatrutide and survodutide on their own sponsors' figures, caveats stated
The Sanofi deal terms and the target map that shows which Dupixent pathway each antibody covers
The movers table: five Thursday closes that carry a story, including Foghorn's 18.2% repricing
📋 The Week in Review
Monday: Kodiak's Zenkuda met both DAYBREAK endpoints with 54% of patients on six month dosing; Mirum's brelovitug hit in hepatitis delta while AZURE-1 showed the interval's cost; AstraZeneca took a $2 billion Summit stake.
Tuesday: retatrutide cut weight 20.8% in TRIUMPH-2; uniQure's Huntington's benefit weakened at 48 months; Beam sued two rivals over base editing.
Wednesday: Lilly's one day double, EloraTZP at 23.3% and Foundayo's clean cardiovascular line with a mortality surprise; CMS finalized the GLOBE rule; OCTANE's pill switchers kept losing; Camzyos went pediatric; Abbott launched SimpleScreen.
Thursday: COURAGE's 52 week primary landed and paid off our Tuesday figure cut; survodutide hit 13.1% and the market shrugged; Sanofi paid Regeneron $1 billion; the Foghorn and Lilly collaboration ended on efficacy; Cullinan opened the first line zipalertinib NDA after the close.
The through line: set Monday as watch the delivery layer, graded today as paid off. Molecules converged, one converged short, and the differentiation moved to interval, route, titration, and now composition.
🔒 BioMed Nexus Pro
In Today's Pro Brief...
🧠 The anatomy of a franchise succession: what Sanofi's $1 billion really buys, and the receptor choice that tells you exactly how worried the partners are
💊 The obesity leaderboard after Milan: where 13.1% leaves Boehringer and Zealand, and the number that decides whether muscle preservation becomes a label claim
📊 Synthetic lethality after FHD-909: which programs inherit the burden of proof, and what Oura's delay says about the exit window everyone is modeling
🎯 Plus the full catalyst calendar rebuilt for the post EASD stretch: October's price watches, the November decision cluster, and the quarter end queue
The delivery layer week closed graded: molecules converged, one converged short, and the differentiation moved to interval, route, titration and composition. Our Tuesday figure cut on COURAGE paid off in Thursday's primary, which is the protocol doing its job. Monday sets the new through line. What are you watching? Reply to this email.
Sponsorship slots for 2026 are limited. See packages and pricing →
NEW: BioMed Nexus Signals, weekly sales intelligence for life sciences BD teams. Learn more →